Therapeutic targeting of gut microbial contribution to cardiometabolic disease
21 September 2016 12:00 to 13:00 EDT
220 Mass. Avenue, Cambridge MA - USA
Speaker: Stanley L. Hazen MD, PhD Chair, Department of Cellular & Molecular Medicine Vice Chair, Translational Research, Lerner Research Institute Section Head, Preventative Cardiology & Rehabilitation Director, Center for Microbiome and Human Health The Cleveland Clinic Foundation
Seminar Abstract: This presentation will discuss the recent finding that ingestion of specific dietary nutrients with trimethylamine (TMA) moieties, such as from phosphatidylcholine, choline or carnitine, through a meta-organismal pathway (gut microbe and host hepatic enzyme), leads to generation of the pro-atherogenic metabolite trimethylamine-N-oxide (TMAO). Both clinical and basic studies will be discussed revealing the involvement of the TMAO pathway in development of atherosclerosis, thrombosis, and alterations in vascular tissue gene expression and sterol metabolism. The contributory role of the TMAO pathway in CVD and end-organ disease development in vulnerable patient populations including CKD, HF and DM will be discussed. Finally, we will review recently reported studies revealing the potential for dietary, genetic and pharmacological targeting of processes involved in TMAO generation as a novel therapeutic approach for the treatment of CVD in these vulnerable populations.
Entry instructions: There is no cost to attend the seminar. If you are interested in attending please contact Meghan Somers. Please check in with security at the Novartis visitor's entrance of 220 Massachusetts Avenue and you will be directed to the location of the seminar.
Stanley L. Hazen - image
Speaker | Stanley L. Hazen MD, PhD
Dr Hazen received both his PhD in Biophysical Chemistry and Molecular Biology and medical degree at Washington University School of Medicine in St. Louis. He has been at the Cleveland Clinic since 1997, where he serves as the Chair of the Department of Cellular and Molecular Medicine at the Cleveland Clinic’s Lerner Research Institute. He is also the Section Head of Preventive Cardiology & Rehabilitation at the Cleveland Clinic, and holds both the Jan Bleeksma Chair in Vascular Cell Biology and Atherosclerosis, and the Leonard Krieger Chair in Preventive Cardiology. Dr. Hazen has published over 300 peer reviewed publications, including many in top tier clinical and basic science journals alike. He has been elected as member to honorary clinical and basic science societies including ASCI in 2003, the AAP in 2007, and in 2008 he was elected as a Fellow to the American Association for the Advancement of Science (AAAS).
Dr. Hazen’s laboratory focuses on understanding mechanisms through which inflammation contributes to diseases such as atherosclerosis. His work is highly innovative, and has led to numerous discoveries in multiple areas of cardiovascular disease research. His discovery of a mechanistic link between gut microbes and cardiovascular disease was awarded as an Inaugural recipient of a “Top 10 Clinical Discovery of the Year (2011)” award by the Clinical Research Forum (April, 2012), which is comprised of leadership at NHLBI, academia and industry. His further studies on the gut microbe – cardiovascular disease connection were recognized by the American Heart Association and the American Stroke Association in 2014 as a “2013 top 10 advances in heart disease and stroke science”.